Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03497702
Other study ID # NCC2017-0110
Secondary ID
Status Recruiting
Phase Phase 2
First received March 18, 2018
Last updated April 12, 2018
Start date May 8, 2017
Est. completion date January 2024

Study information

Verified date April 2018
Source National Cancer Center, Korea
Contact Keun Seok Lee, MD, PhD
Phone +82-31-920-1220
Email kslee@ncc.re.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an exploratory interventional study that initiates chemotherapy with letrozole in patients with estrogen receptor positive/HER2-negative breast cancer preoperably.


Description:

STUDY RATIONALE: Patients with ER+/HER2- operable breast cancers who are candiate of neoadjuant chemotherapy generally receive chemotherapy alone before operation, followed by adjuvant endocrine therapy. Because endocrine therapy is primarily delivered in the postoperative setting, the ability to add the efficacy of aromatase inhibitors combined with chemotherapy is lost. This study offers the unique opportunity to assess the synergistic or additive responsiveness of breast tumors to endocrine therapy plus chemotherapy while the tumors are still in vivo by treating patients with an aromatast inhibitor combined with chemotherapy before surgery and assessing pCR rates.

PRIMARY OBJECTIVE: The primary objective is to determine the frequency of pCR in breast and axilla.


Recruitment information / eligibility

Status Recruiting
Enrollment 114
Est. completion date January 2024
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender Female
Age group 19 Years to 70 Years
Eligibility Inclusion Criteria:

- Pathologically proven breast cancer patients who are candidate of neoadjuvant chemotherapy with AC followed by Docetaxel

- Age: 19-70 years

- ER or PR positive ,cT2-3N0 or cT1-3/N+ M0 (ER-positive =1% nuclear staining by immunohistochemistry , Allred score=3 )

- Available FFPE tissue for biomarker study

- HER2-negative by ASCO/CAP guideline

- Patients who agree to adequate contraception

- ECOG scores of 0-2

- Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions

- Patients who provide consent

Exclusion Criteria:

- Inflammatory breast cancer

- Distant metastasis

- Cerebral vascular accidents including transient ischemic attack

- Pulmanary thromboembolism or deep vein thrombosis with 6 months; however, patients who received more than 6 weeks of anticoagulation within 6 months and remains asymptomatic are eligible.

- With a history of malignant tumor or complicated with other malignant tumors in addition to breast cancer, except for non-melanoma skin cancer, curatively resected early gastric cancer, differentiated thyoid cancer < 1 cm, or other cured malignant tumor without recurrence for at least 3 years

- Ejection Fraction <55% by MUGA scan / Echo CG

- No available tissue for biomarker study

- Pregnant or lactating women

- Patients with other serious diseases or medical conditions: Pituitary adenoma, Malabsorption syndrome, Major resection of gastrointestinal tract, Corrected QT interval > 480 msec, Congestive heart failure or unstable angina pectoris, myocardial infarction, stent insertion, angioplasty, coronary bypass surgery, symptomatic peripheral artery disease within 6 months before the enrollment

- NYHA class III or IV congestive heart failure

- Uncontrolled hypertension and uncontrolled high-risk arrhythmia considered by the investigator

- Major surgery, major trauma, and/or unhealed wound, fracture, or ulcer within 4 weeks

- Acute hemorrhage or hemorrhagic tendency

- Obvious neurological or psychiatric disorders, including psychosis, epileptic dementia and other diseases which may affect the understanding and sign of the informed consent

- Uncontrolled acute infection

- Patients with allergic constitution and any known or suspected drug allergy

- Concurrent use of other investigational drugs; or participating in other clinical trials involving investigational drugs within 30 days before this study

- Patients with mental illness or other conditions affecting the patient compliance

- Not suitable for the trial considered by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxorubicin
60mg/m2 IV every 3 weeks for 4 cycles
Cyclophosphamide
600mg/m2 IV every 3 weeks for 4 cycles
Docetaxel
75mg/m2 IV every 3 weeks for 4 cycles
Letrozole
2.5 mg once daily preoperably
leuprorelin
3.75 mg SC every 4 weeks for premenopausal patients

Locations

Country Name City State
Korea, Republic of National Cancer Center Goyang-si

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Center, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary pathologic complete remission (pCR) pCR defined as no invasive residuals in breast and lymph nodes (ypT0/Tis, ypN0 [MD Anderson definition]) within 6 weeks following the last dose of chemotherapy
Secondary Adverse events Frequency and severity of hematological and non-hematological adverse events and laboratory abnormalities according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 during 6 months of neoadjuvant chemotherapy
Secondary Response rate Overall objective clinical response rate = CR + PR rate, measured by MRI (or US) and assessed by RECIST criteria. during 6 months of neoadjuvant chemotherapy
Secondary Downstaging to breast conserving surgery (BCS) Ratio of the number of patients with breast conserving surgery converted from planned mastectomy over the number of patients with initially planned mastectomy within 6 weeks following the last dose of chemotherapy
Secondary Disease free survival Disease-free survival (DFS) following operation. Patients will be followed up to 6 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2